No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2020-12, Vol.111 (12), p.4490-4499 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4499 |
|---|---|
| container_issue | 12 |
| container_start_page | 4490 |
| container_title | Cancer science |
| container_volume | 111 |
| creator | Toriyama, Eo Hata, Tomoko Yokota, Ken‐ichi Chiwata, Masahiko Kamijo, Rena Hashimoto, Miki Taguchi, Masataka Horai, Makiko Matsuo, Masatoshi Matsuo, Emi Takasaki, Yumi Kawaguchi, Yasuhisa Itonaga, Hidehiro Sato, Shinya Ando, Koji Sawayama, Yasushi Taguchi, Jun Imaizumi, Yoshitaka Tsushima, Hideki Jo, Tatsuro Yoshida, Shinichiro Moriuchi, Yukiyoshi Miyazaki, Yasushi |
| description | The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P |
| doi_str_mv | 10.1111/cas.14653 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7734160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710750710</galeid><sourcerecordid>A710750710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5623-93e01faf3d7dd6092f25dd67d6ab9057ebf3d94b6dc7c0bed7bf1fe929c426583</originalsourceid><addsrcrecordid>eNp9ks1u1DAQxyMEoh9w4AWQJU49ZOuPxF5zQFqt-JKqcgDOlmOPF7dJvNhJqnDiEfqMPAnebilUAmzJHtm_-c94PEXxjOAFyePU6LQgFa_Zg-KQsEqWAmP-8MYWpcSMHhRHKV1gzHglq8fFAaOSySUXh8V0HpBpQUeUxjj5SbeogR6cH1BwSH_Txg_e-h6QCxG14Qrij-_X0adL1M3QBjunbavT4A1Kc29j6CC9RCsUYYghbcEMfgKUhtHOO8FzvdFJX_onxSOn2wRPb_fj4vOb15_W78qzD2_fr1dnpak5ZaVkgInTjllhLceSOlpnQ1iuG4lrAU2-klXDrREGN2BF44gDSaWpKK-X7Lh4tdfdjk0H1kA_RN2qbfSdjrMK2qv7N73_ojZhUkKwinCcBV7cCsTwdYQ0qIswxj7nrGhdUyk4J_K_VMUlz7nS5W9qo1tQvnchhzSdT0atBMGixnnN1OIvVJ4WOm_C7m_y-T2Hk72DyRVPEdzd8whWu_5QuT_UTX9k9vmf9bgjfzVEBk73wFWOMv9bSa1XH_eSPwGm6McJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2469690528</pqid></control><display><type>article</type><title>No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Toriyama, Eo ; Hata, Tomoko ; Yokota, Ken‐ichi ; Chiwata, Masahiko ; Kamijo, Rena ; Hashimoto, Miki ; Taguchi, Masataka ; Horai, Makiko ; Matsuo, Masatoshi ; Matsuo, Emi ; Takasaki, Yumi ; Kawaguchi, Yasuhisa ; Itonaga, Hidehiro ; Sato, Shinya ; Ando, Koji ; Sawayama, Yasushi ; Taguchi, Jun ; Imaizumi, Yoshitaka ; Tsushima, Hideki ; Jo, Tatsuro ; Yoshida, Shinichiro ; Moriuchi, Yukiyoshi ; Miyazaki, Yasushi</creator><creatorcontrib>Toriyama, Eo ; Hata, Tomoko ; Yokota, Ken‐ichi ; Chiwata, Masahiko ; Kamijo, Rena ; Hashimoto, Miki ; Taguchi, Masataka ; Horai, Makiko ; Matsuo, Masatoshi ; Matsuo, Emi ; Takasaki, Yumi ; Kawaguchi, Yasuhisa ; Itonaga, Hidehiro ; Sato, Shinya ; Ando, Koji ; Sawayama, Yasushi ; Taguchi, Jun ; Imaizumi, Yoshitaka ; Tsushima, Hideki ; Jo, Tatsuro ; Yoshida, Shinichiro ; Moriuchi, Yukiyoshi ; Miyazaki, Yasushi</creatorcontrib><description>The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.
Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.14653</identifier><identifier>PMID: 32939867</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antimitotic agents ; Antineoplastic agents ; Azacitidine - adverse effects ; Azacitidine - therapeutic use ; Care and treatment ; Cause of Death ; characteristics and pathology of human cancer ; Chemotherapy ; chemotherapy and endocrine therapy ; Comorbidity ; Comparative analysis ; epigenetic therapy ; Erythrocyte Transfusion - mortality ; Erythrocytes ; Erythropoiesis ; Female ; Hematinics - therapeutic use ; Hematology ; hematopoietic organ ; Humans ; Immunosuppressive agents ; Immunosuppressive Agents - therapeutic use ; Immunotherapy ; Induction Chemotherapy - methods ; Japan ; Kaplan-Meier Estimate ; Leukemia ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Multivariate Analysis ; Myelodysplastic syndrome ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - mortality ; Original ; Patients ; Platelet Transfusion - mortality ; Prognosis ; Regression Analysis ; Remission ; Remission (Medicine) ; Retrospective Studies ; Sex Factors ; Statistical analysis ; Stem cell transplantation ; Stem cells ; Treatment Outcome ; Young Adult</subject><ispartof>Cancer science, 2020-12, Vol.111 (12), p.4490-4499</ispartof><rights>2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5623-93e01faf3d7dd6092f25dd67d6ab9057ebf3d94b6dc7c0bed7bf1fe929c426583</citedby><cites>FETCH-LOGICAL-c5623-93e01faf3d7dd6092f25dd67d6ab9057ebf3d94b6dc7c0bed7bf1fe929c426583</cites><orcidid>0000-0002-0642-5814 ; 0000-0002-2954-5691 ; 0000-0002-9115-1749</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734160/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734160/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32939867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toriyama, Eo</creatorcontrib><creatorcontrib>Hata, Tomoko</creatorcontrib><creatorcontrib>Yokota, Ken‐ichi</creatorcontrib><creatorcontrib>Chiwata, Masahiko</creatorcontrib><creatorcontrib>Kamijo, Rena</creatorcontrib><creatorcontrib>Hashimoto, Miki</creatorcontrib><creatorcontrib>Taguchi, Masataka</creatorcontrib><creatorcontrib>Horai, Makiko</creatorcontrib><creatorcontrib>Matsuo, Masatoshi</creatorcontrib><creatorcontrib>Matsuo, Emi</creatorcontrib><creatorcontrib>Takasaki, Yumi</creatorcontrib><creatorcontrib>Kawaguchi, Yasuhisa</creatorcontrib><creatorcontrib>Itonaga, Hidehiro</creatorcontrib><creatorcontrib>Sato, Shinya</creatorcontrib><creatorcontrib>Ando, Koji</creatorcontrib><creatorcontrib>Sawayama, Yasushi</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><creatorcontrib>Imaizumi, Yoshitaka</creatorcontrib><creatorcontrib>Tsushima, Hideki</creatorcontrib><creatorcontrib>Jo, Tatsuro</creatorcontrib><creatorcontrib>Yoshida, Shinichiro</creatorcontrib><creatorcontrib>Moriuchi, Yukiyoshi</creatorcontrib><creatorcontrib>Miyazaki, Yasushi</creatorcontrib><title>No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.
Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Azacitidine - adverse effects</subject><subject>Azacitidine - therapeutic use</subject><subject>Care and treatment</subject><subject>Cause of Death</subject><subject>characteristics and pathology of human cancer</subject><subject>Chemotherapy</subject><subject>chemotherapy and endocrine therapy</subject><subject>Comorbidity</subject><subject>Comparative analysis</subject><subject>epigenetic therapy</subject><subject>Erythrocyte Transfusion - mortality</subject><subject>Erythrocytes</subject><subject>Erythropoiesis</subject><subject>Female</subject><subject>Hematinics - therapeutic use</subject><subject>Hematology</subject><subject>hematopoietic organ</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Immunotherapy</subject><subject>Induction Chemotherapy - methods</subject><subject>Japan</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - mortality</subject><subject>Original</subject><subject>Patients</subject><subject>Platelet Transfusion - mortality</subject><subject>Prognosis</subject><subject>Regression Analysis</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Retrospective Studies</subject><subject>Sex Factors</subject><subject>Statistical analysis</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ks1u1DAQxyMEoh9w4AWQJU49ZOuPxF5zQFqt-JKqcgDOlmOPF7dJvNhJqnDiEfqMPAnebilUAmzJHtm_-c94PEXxjOAFyePU6LQgFa_Zg-KQsEqWAmP-8MYWpcSMHhRHKV1gzHglq8fFAaOSySUXh8V0HpBpQUeUxjj5SbeogR6cH1BwSH_Txg_e-h6QCxG14Qrij-_X0adL1M3QBjunbavT4A1Kc29j6CC9RCsUYYghbcEMfgKUhtHOO8FzvdFJX_onxSOn2wRPb_fj4vOb15_W78qzD2_fr1dnpak5ZaVkgInTjllhLceSOlpnQ1iuG4lrAU2-klXDrREGN2BF44gDSaWpKK-X7Lh4tdfdjk0H1kA_RN2qbfSdjrMK2qv7N73_ojZhUkKwinCcBV7cCsTwdYQ0qIswxj7nrGhdUyk4J_K_VMUlz7nS5W9qo1tQvnchhzSdT0atBMGixnnN1OIvVJ4WOm_C7m_y-T2Hk72DyRVPEdzd8whWu_5QuT_UTX9k9vmf9bgjfzVEBk73wFWOMv9bSa1XH_eSPwGm6McJ</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Toriyama, Eo</creator><creator>Hata, Tomoko</creator><creator>Yokota, Ken‐ichi</creator><creator>Chiwata, Masahiko</creator><creator>Kamijo, Rena</creator><creator>Hashimoto, Miki</creator><creator>Taguchi, Masataka</creator><creator>Horai, Makiko</creator><creator>Matsuo, Masatoshi</creator><creator>Matsuo, Emi</creator><creator>Takasaki, Yumi</creator><creator>Kawaguchi, Yasuhisa</creator><creator>Itonaga, Hidehiro</creator><creator>Sato, Shinya</creator><creator>Ando, Koji</creator><creator>Sawayama, Yasushi</creator><creator>Taguchi, Jun</creator><creator>Imaizumi, Yoshitaka</creator><creator>Tsushima, Hideki</creator><creator>Jo, Tatsuro</creator><creator>Yoshida, Shinichiro</creator><creator>Moriuchi, Yukiyoshi</creator><creator>Miyazaki, Yasushi</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0642-5814</orcidid><orcidid>https://orcid.org/0000-0002-2954-5691</orcidid><orcidid>https://orcid.org/0000-0002-9115-1749</orcidid></search><sort><creationdate>202012</creationdate><title>No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki</title><author>Toriyama, Eo ; Hata, Tomoko ; Yokota, Ken‐ichi ; Chiwata, Masahiko ; Kamijo, Rena ; Hashimoto, Miki ; Taguchi, Masataka ; Horai, Makiko ; Matsuo, Masatoshi ; Matsuo, Emi ; Takasaki, Yumi ; Kawaguchi, Yasuhisa ; Itonaga, Hidehiro ; Sato, Shinya ; Ando, Koji ; Sawayama, Yasushi ; Taguchi, Jun ; Imaizumi, Yoshitaka ; Tsushima, Hideki ; Jo, Tatsuro ; Yoshida, Shinichiro ; Moriuchi, Yukiyoshi ; Miyazaki, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5623-93e01faf3d7dd6092f25dd67d6ab9057ebf3d94b6dc7c0bed7bf1fe929c426583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Azacitidine - adverse effects</topic><topic>Azacitidine - therapeutic use</topic><topic>Care and treatment</topic><topic>Cause of Death</topic><topic>characteristics and pathology of human cancer</topic><topic>Chemotherapy</topic><topic>chemotherapy and endocrine therapy</topic><topic>Comorbidity</topic><topic>Comparative analysis</topic><topic>epigenetic therapy</topic><topic>Erythrocyte Transfusion - mortality</topic><topic>Erythrocytes</topic><topic>Erythropoiesis</topic><topic>Female</topic><topic>Hematinics - therapeutic use</topic><topic>Hematology</topic><topic>hematopoietic organ</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Immunotherapy</topic><topic>Induction Chemotherapy - methods</topic><topic>Japan</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - mortality</topic><topic>Original</topic><topic>Patients</topic><topic>Platelet Transfusion - mortality</topic><topic>Prognosis</topic><topic>Regression Analysis</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Retrospective Studies</topic><topic>Sex Factors</topic><topic>Statistical analysis</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toriyama, Eo</creatorcontrib><creatorcontrib>Hata, Tomoko</creatorcontrib><creatorcontrib>Yokota, Ken‐ichi</creatorcontrib><creatorcontrib>Chiwata, Masahiko</creatorcontrib><creatorcontrib>Kamijo, Rena</creatorcontrib><creatorcontrib>Hashimoto, Miki</creatorcontrib><creatorcontrib>Taguchi, Masataka</creatorcontrib><creatorcontrib>Horai, Makiko</creatorcontrib><creatorcontrib>Matsuo, Masatoshi</creatorcontrib><creatorcontrib>Matsuo, Emi</creatorcontrib><creatorcontrib>Takasaki, Yumi</creatorcontrib><creatorcontrib>Kawaguchi, Yasuhisa</creatorcontrib><creatorcontrib>Itonaga, Hidehiro</creatorcontrib><creatorcontrib>Sato, Shinya</creatorcontrib><creatorcontrib>Ando, Koji</creatorcontrib><creatorcontrib>Sawayama, Yasushi</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><creatorcontrib>Imaizumi, Yoshitaka</creatorcontrib><creatorcontrib>Tsushima, Hideki</creatorcontrib><creatorcontrib>Jo, Tatsuro</creatorcontrib><creatorcontrib>Yoshida, Shinichiro</creatorcontrib><creatorcontrib>Moriuchi, Yukiyoshi</creatorcontrib><creatorcontrib>Miyazaki, Yasushi</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toriyama, Eo</au><au>Hata, Tomoko</au><au>Yokota, Ken‐ichi</au><au>Chiwata, Masahiko</au><au>Kamijo, Rena</au><au>Hashimoto, Miki</au><au>Taguchi, Masataka</au><au>Horai, Makiko</au><au>Matsuo, Masatoshi</au><au>Matsuo, Emi</au><au>Takasaki, Yumi</au><au>Kawaguchi, Yasuhisa</au><au>Itonaga, Hidehiro</au><au>Sato, Shinya</au><au>Ando, Koji</au><au>Sawayama, Yasushi</au><au>Taguchi, Jun</au><au>Imaizumi, Yoshitaka</au><au>Tsushima, Hideki</au><au>Jo, Tatsuro</au><au>Yoshida, Shinichiro</au><au>Moriuchi, Yukiyoshi</au><au>Miyazaki, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2020-12</date><risdate>2020</risdate><volume>111</volume><issue>12</issue><spage>4490</spage><epage>4499</epage><pages>4490-4499</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.
Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>32939867</pmid><doi>10.1111/cas.14653</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0642-5814</orcidid><orcidid>https://orcid.org/0000-0002-2954-5691</orcidid><orcidid>https://orcid.org/0000-0002-9115-1749</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2020-12, Vol.111 (12), p.4490-4499 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7734160 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Adult Age Factors Aged Aged, 80 and over Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antimitotic agents Antineoplastic agents Azacitidine - adverse effects Azacitidine - therapeutic use Care and treatment Cause of Death characteristics and pathology of human cancer Chemotherapy chemotherapy and endocrine therapy Comorbidity Comparative analysis epigenetic therapy Erythrocyte Transfusion - mortality Erythrocytes Erythropoiesis Female Hematinics - therapeutic use Hematology hematopoietic organ Humans Immunosuppressive agents Immunosuppressive Agents - therapeutic use Immunotherapy Induction Chemotherapy - methods Japan Kaplan-Meier Estimate Leukemia Male Medical prognosis Medical research Medicine, Experimental Middle Aged Multivariate Analysis Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - mortality Original Patients Platelet Transfusion - mortality Prognosis Regression Analysis Remission Remission (Medicine) Retrospective Studies Sex Factors Statistical analysis Stem cell transplantation Stem cells Treatment Outcome Young Adult |
| title | No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T17%3A47%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20clear%20survival%20benefit%20of%20azacitidine%20for%20lower%E2%80%90risk%20myelodysplastic%20syndromes:%20A%20retrospective%20study%20of%20Nagasaki&rft.jtitle=Cancer%20science&rft.au=Toriyama,%20Eo&rft.date=2020-12&rft.volume=111&rft.issue=12&rft.spage=4490&rft.epage=4499&rft.pages=4490-4499&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.14653&rft_dat=%3Cgale_pubme%3EA710750710%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2469690528&rft_id=info:pmid/32939867&rft_galeid=A710750710&rfr_iscdi=true |